Embla Medical Hf S/Adr (OSSUY) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

At this time, I would like to welcome everyone to this Q3 2025 conference call. Today's call is being recorded. If you have any objections, please disconnect at this time. All participants will be on listen-only mode throughout the presentation, and afterwards there will be a question and answer session. I would now like to introduce President and CEO Svend Selvason and CFO Anna Svendstadir. I will now send a call over to your speakers. You may now begin your presentation. Thank you, operator. And good morning and welcome to the Ampla Medical Conference call where we will review the third quarter of 2025. I am Svend Selvason, President and CEO of Ampla Medical. And joining me on today's call from Copenhagen is our Chief Financial Officer, Artur Svensdottir, and Angela Merikos, Head of Investor Relations at Kaussintag. The presentation should take approximately 15 minutes, after which there will be an opportunity to ask questions during a Q&A session. And if you please go to the next slide. Sales in the third quarter amounted to 237 million, representing 7% organic growth, And our reported growth was 11% for the quarter, including three percentage point impact from FX and one percentage point from M&A. As expected, and as we had communicated, our growth picked up here in the third quarter, driven principally by double-digit growth in prosthetics and neuro-orthotics, while sales growth in patient care remained modest, and sales and fundraising and support segment came in flat for the quarter. The EBITDA margin was strong at 22% here in the coaster and on par with the coaster last year, while our margin increased by a full percentage point to 21% for the first nine months compared to the same period last year. The margin increase was driven by robust sales in prosthetic...